Peptide Schedule
Linaclotide (Linzess)14 residuesCCEYCCNPACTGCYEach bubble = one amino acid. Size = residue mass. Color = chemical class.Linaclotide (Linzess)
Benefits
About Linaclotide (Linzess)
Linaclotide (brand name Linzess/Constella) is a synthetic 14-amino-acid peptide and first-in-class guanylate cyclase-C (GC-C) agonist approved by the FDA in 2012 for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Structurally related to the endogenous hormones guanylin and uroguanylin, linaclotide contains three intramolecular disulfide bonds (Cys1-Cys6, Cys2-Cys10, Cys5-Cys13) that lock it into a compact, protease-resistant conformation. It is one of the rare peptide therapeutics designed for oral administration — the capsule survives gastric acid, and the peptide acts locally on the luminal surface of intestinal epithelial cells without entering the bloodstream. Upon binding GC-C receptors, linaclotide triggers intracellular cGMP production, which activates CFTR chloride channels and drives fluid secretion into the intestinal lumen, accelerating transit. Extracellular cGMP also modulates visceral afferent nerve signaling, reducing abdominal pain — a dual mechanism that addresses both constipation and visceral hypersensitivity. Two pivotal Phase 3 trials demonstrated that 290 mcg daily significantly improved IBS-C symptoms, with approximately 34% of patients meeting the FDA composite responder endpoint versus 14-21% on placebo (NNT of 5-8). For CIC, Phase 3 trials of 145 mcg and 290 mcg met primary efficacy endpoints with NNT of 6-10. The drug has an excellent safety profile with diarrhea (14-20%) as the most common side effect — a pharmacological extension of its mechanism rather than an off-target toxicity.
Who Should Consider Linaclotide (Linzess)
- Adults with irritable bowel syndrome with constipation (IBS-C) — FDA-approved at 290 mcg daily
- Adults with chronic idiopathic constipation (CIC) — FDA-approved at 72 mcg or 145 mcg daily
- Pediatric patients aged 6-17 with functional constipation — FDA-approved at 72 mcg daily
- Patients who have failed osmotic laxatives, fiber supplements, or other first-line constipation therapies
- IBS-C patients with significant abdominal pain who need both motility and analgesic benefits
How Linaclotide (Linzess) Works
Linaclotide is a 14-amino-acid synthetic peptide structurally homologous to endogenous guanylin and uroguanylin. It binds to and activates guanylate cyclase-C (GC-C) receptors expressed on the apical (luminal) surface of intestinal epithelial cells. GC-C activation catalyzes the conversion of GTP to cyclic guanosine monophosphate (cGMP), raising intracellular cGMP concentrations. Elevated cGMP activates cGMP-dependent protein kinase II (PKG-II), which phosphorylates and opens the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. CFTR activation drives secretion of chloride and bicarbonate ions into the intestinal lumen, creating an osmotic gradient that pulls water into the gut, increasing luminal fluid volume, softening stool, and accelerating colonic transit. In parallel, intracellular cGMP is exported to the extracellular (submucosal) space via multidrug resistance protein 4 (MRP4) efflux pumps. This extracellular cGMP acts on colonic afferent nerve endings to reduce the firing threshold of visceral nociceptors, decreasing visceral hypersensitivity and abdominal pain — the hallmark symptom of IBS-C. Linaclotide is metabolized in the small intestine by loss of its C-terminal tyrosine to form the active metabolite MM-419447, which retains full GC-C agonist activity. Both parent drug and metabolite are degraded within 1 hour in intestinal fluid through disulfide bond reduction, ensuring purely local activity with no systemic exposure.
What to Expect
Begin once-daily dosing on an empty stomach 30 minutes before breakfast. Increased bowel movements may occur within 24 hours. Some patients experience loose stools or diarrhea in the first few days as the gut adjusts to increased fluid secretion. This typically self-resolves.
Improvement in stool frequency and consistency is often measurable within the first week. Complete spontaneous bowel movements (CSBMs) increase. Abdominal bloating may begin to reduce. If diarrhea is persistent or severe, dose reduction (290 mcg to 145 mcg, or 145 mcg to 72 mcg) is appropriate.
Sustained improvement in bowel habits. Abdominal pain reduction becomes more apparent as extracellular cGMP accumulates and modulates visceral afferent nerve signaling. In Phase 3 IBS-C trials, significant separation from placebo in pain scores was evident by week 2-3.
Full therapeutic benefit established. In clinical trials, approximately 34% of IBS-C patients met the FDA composite responder endpoint (improvement in both pain and stool frequency) over 12 weeks. Benefits are sustained with continued daily dosing. No tolerance or dose escalation needed.
Long-term maintenance phase. A 26-week Phase 3 trial confirmed sustained efficacy without diminishing returns. Discontinuation leads to symptom recurrence within approximately 1 week, confirming the need for ongoing therapy. Annual reassessment with prescribing physician is recommended.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 72mcg | Daily |
| Moderate | 145mcg | Daily |
| Aggressive | 290mcg | Daily |
Note: Linaclotide is an oral peptide capsule — no injection or reconstitution required. It is one of the few FDA-approved peptide drugs taken by mouth. It acts entirely within the gut lumen with negligible systemic absorption (<0.1% bioavailability). Take on an empty stomach at least 30 minutes before the first meal of the day. The 72 mcg dose is approved for chronic idiopathic constipation (CIC) and pediatric functional constipation (ages 6-17). The 145 mcg dose is for CIC in adults. The 290 mcg dose is specifically for IBS-C in adults. Do NOT use in children under 6 years — contraindicated due to risk of severe dehydration.
How to Inject Linaclotide (Linzess)
Linaclotide is taken orally as a capsule once daily on an empty stomach, at least 30 minutes before the first meal of the day. Swallow the capsule whole — do not break, crush, or chew. For patients who have difficulty swallowing, the capsule may be opened and the beads sprinkled into applesauce or administered via a nasogastric or gastrostomy tube with water. Do not mix with other foods or liquids. No injection, reconstitution, or refrigeration is required. This is one of the rare peptide drugs designed specifically for oral delivery — the three-disulfide-bond structure confers gastric acid stability, and the peptide exerts its therapeutic effects entirely within the gut lumen.
Cycling Protocol
Linaclotide is intended for continuous daily use, not cycled. Clinical trials ran 12-26 weeks of uninterrupted dosing with sustained efficacy and no evidence of tachyphylaxis or tolerance. The FDA label does not specify a maximum treatment duration. Symptoms typically return within 1 week of discontinuation, as demonstrated in the 4-week randomized withdrawal phase of a Phase 3 IBS-C trial. Patients should continue taking linaclotide daily as long as the prescribing physician recommends.
Pharmacokinetics
Source: Systemic half-life is not measurable — linaclotide plasma concentrations are below the limit of quantification after therapeutic doses (72-290 mcg). The peptide and its active metabolite MM-419447 are degraded within ~1 hour in the intestinal lumen through disulfide bond reduction. The 0.05-hour value represents a nominal placeholder; the drug has no meaningful systemic PK (FDA label, Section 12.3)
Loading the interactive decay curve.
Side Effects
Diarrhea is the most common side effect, reported in 14-20% of patients in clinical trials (vs. 3-5% placebo). It is dose-dependent and typically mild to moderate, resolving with dose reduction or discontinuation. Severe diarrhea requiring hospitalization has been reported in rare postmarketing cases, sometimes accompanied by dizziness, syncope, hypotension, or electrolyte abnormalities (hypokalemia, hyponatremia). Other reported effects include abdominal pain, flatulence, abdominal distension, and headache, all at low rates. Nausea is rare. There is a boxed warning against use in children under 6 years of age due to risk of serious dehydration, and it is not recommended in patients 6-17 years for IBS-C (only approved for functional constipation in this age group at 72 mcg).
Contraindications
- Children under 6 years of age — BOXED WARNING: risk of serious dehydration due to immature GC-C receptor expression and heightened secretory response
- Known or suspected mechanical gastrointestinal obstruction
- Known hypersensitivity to linaclotide or any capsule excipients
- Pregnancy — Category C; insufficient human data, embryofetal toxicity not observed in animal studies but use only if benefit outweighs risk
- Breastfeeding — linaclotide and its metabolite are not absorbed systemically, but caution is advised due to limited data
- Not recommended for IBS-C in patients aged 6-17 years (only approved for functional constipation in this age group)
Drug Interactions
- Proton pump inhibitors (omeprazole, lansoprazole) — may alter capsule dissolution timing; clinical significance unclear but no dose adjustment required per FDA label
- Other secretagogues (lubiprostone, plecanatide) — avoid concurrent use due to additive diarrhea risk and overlapping mechanisms
- Antidiarrheal agents (loperamide) — may counteract linaclotide's therapeutic effect; concurrent use undermines treatment rationale
- Diuretics and ACE inhibitors — monitor for electrolyte imbalances if linaclotide-induced diarrhea is significant, particularly hypokalemia and hyponatremia
- Drugs with narrow therapeutic index requiring consistent GI absorption (warfarin, digoxin, levothyroxine) — increased intestinal fluid could theoretically alter absorption kinetics; monitor levels
Storage & Stability
Molecular Profile
Related Peptides
References
- Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety (Chey et al., Am J Gastroenterol 2012)PubMed 22986437
- A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation (Rao et al., Am J Gastroenterol 2012)PubMed 22986440
- Linaclotide in chronic idiopathic constipation patients with moderate to severe abdominal bloating: a randomized, controlled trial (Lacy et al., PLoS One 2015)PubMed 26222318
- A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation (Johnston et al., Curr Med Res Opin 2013)Review
- LINZESS (linaclotide) capsules — FDA Full Prescribing Information (2025)FDA Label